Healthcare professionals and management at a meeting
© sturti / Getty Images

Case Clinic Series

    alt txt

    properties.trackTitle

    properties.trackSubtitle

    This series presents individual medical cases that feature challenging conditions, uncommon diseases, or an unusual presentation of symptoms. In each case, our team summarizes, explains our research and analysis, and suggests an underwriting recommendation. Munich Re’s team of global medical directors routinely conducts rigorous analyses of the latest medical advances so that primary insurers and society alike can benefit from evidence-informed risk assessments. It is our hope that exploring compelling cases will foster a greater understanding of medical research and awareness of new medical innovations and emerging risks while ultimately expanding insurability.
    The Munich Re medical team assessed a 50-year-old applicant with obesity and a history of severe sleep apnea. After treatment, follow-ups showed a remarkable return to normal health. The key question to answer: "How does this impact their insurability?"
    The Munich Re medical team examined the insurability of a woman in her mid-60s with a 10-mm cystic structure on her pancreas, consistent with serous cystadenoma. The key questions to answer in this case: “What’s the appropriate management for this lesion?” and “Is she insurable?”
    The Munich Re medical team investigated the insurability of a person for life/critical illness (CI) insurance with Type 2A Von Willebrand Disease. The case included a history of severe nose bleeds, five ER visits in the past 12 months for the same, and mild iron deficiency. The key questions to answer in this case: “Should bleeding be better controlled before an offer can be made?”
    The Munich Re medical team investigated the insurability of a person who was seen by his doctor a year ago for headaches, and a subsequent MRI of the brain showed a 2 cm arachnoid cyst. The key question to answer in this case: “Does the lesion need to be fully removed with benign pathology before an offer can be made?”  
    The Munich Re medical team investigated the insurability of a person with liver hemangiomas. The question to answer in this case: “Does the lesion need to be fully removed with benign pathology before any offer can be made?”
    Get in touch
    Gina Guzman
    Dr. Gina Guzman
    Vice President & Chief Medical Director
    Munich Re Life US
    Tim Meagher
    Dr. Tim Meagher
    Vice President & Medical Director
    Munich Re, Canada (Life)
    Bradley Heltemes
    Dr. Bradley Heltemes
    Vice President & Medical Director of R&D
    Munich Re Life US
    John F. White III
    Dr. John F. White III
    2nd VP & Medical Director
    Munich Re Life US

    Find out more